Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.

Cancer Clinical Trials:

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.

Cancer Center Trials at St. Barnabas Medical Center.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Study Of Letrozole Extension

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of.

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

These slides were released by the speaker for internal use by Novartis.

HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,

Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.

NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.

The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.

Dubsky P et al. Proc SABCS 2012;Abstract S4-3.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Assistant Professor of Medicine Dana-Farber Cancer Institute

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.

Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy

San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.

Sunil Verma MD, MSEd, FRCPC Medical Oncologist

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Start or Switch?: Latest data from ABCSG/ARNO

Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.

Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.

Copyright © 2010, Research To Practice, All rights reserved. Current Clinical and Future Developmental Paradigms Involving Molecular Pathways in Breast.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.

Anastrozole (‘Arimidex’): a new standard of care?

‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis.

Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.

J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*

CCO Independent Conference Coverage

Perez EA et al. SABCS 2009;Abstract 80.

JOURNAL OF CLINICAL ONCOLOGY 25:

Blackwell KL et al. SABCS 2009;Abstract 61

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

CCO Independent Conference Coverage

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Bergh J et al. SABCS 2009;Abstract 23.

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Presentation transcript:

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting

First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer (EBC) Presented By Eric Winer at 2014 ASCO Annual Meeting

N9831/B-31 Disease-Free Survival Presented By Eric Winer at 2014 ASCO Annual Meeting

Pathologic Response in Neo-ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting

CALGB (TH vs TL vs THL) Presented By Eric Winer at 2014 ASCO Annual Meeting

Adjuvant Lapatinib (ALTTO) Schema Presented By Eric Winer at 2014 ASCO Annual Meeting

Disease Free Survival (DFS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

Disease Free Survival By Hormone Receptor Status Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 9 Presented By Eric Winer at 2014 ASCO Annual Meeting

Overall Survival (OS) Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

Main Differences In AEs By Treatment Arm Presented By Eric Winer at 2014 ASCO Annual Meeting

Thoughts About ALTTO Presented By Eric Winer at 2014 ASCO Annual Meeting

Further Implications for Research and Practice Presented By Eric Winer at 2014 ASCO Annual Meeting

Why Improvement in Pathologic Complete Response May Not Lead to Change in DFS Presented By Eric Winer at 2014 ASCO Annual Meeting

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive Early Breast Cancer: Joint Analysis of IBCSG TEXT and SOFT Presented By Eric Winer at 2014 ASCO Annual Meeting

Study Schemas (Total N=4690) Presented By Eric Winer at 2014 ASCO Annual Meeting

Improved DFS with Exemestane + OFS vs Tamoxifen + OFS Presented By Eric Winer at 2014 ASCO Annual Meeting

Sites of First Failure Presented By Eric Winer at 2014 ASCO Annual Meeting

Overall Survival at 5 Years Presented By Eric Winer at 2014 ASCO Annual Meeting

Women Who Did Not Receive Chemotherapy Presented By Eric Winer at 2014 ASCO Annual Meeting

Selected Adverse Events Presented By Eric Winer at 2014 ASCO Annual Meeting

Adverse Events and QOL Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 23 Presented By Eric Winer at 2014 ASCO Annual Meeting

Does Ovarian Suppression Add To Tamoxifen In Premenopasual Women? Findings FromThe LHRH Meta-Analysis Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 25 Presented By Eric Winer at 2014 ASCO Annual Meeting

Primary End Point: Disease-Free Survival No Significant Difference Between TAM and ANA Presented By Eric Winer at 2014 ASCO Annual Meeting

Is OS + AI The New Standard of Care? Presented By Eric Winer at 2014 ASCO Annual Meeting

What To Consider When You Go Home (1) Presented By Eric Winer at 2014 ASCO Annual Meeting

What To Consider When You Go Home (2) Presented By Eric Winer at 2014 ASCO Annual Meeting

Thank you Presented By Eric Winer at 2014 ASCO Annual Meeting